Loading
A phase 1/2 trial of Elacestrant, Alpelisib, Everolimus, Ribociclib, Palbociclib and Capivasertib in advanced solid tumours, run by Stemline Therapeutics, Inc., active and no longer recruiting.
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer is a phase 1/2 interventional study registered as NCT05563220 by Stemline Therapeutics, Inc., with 435 participants enrolled, started 2023-01-24 and due to reach its primary completion in 2026-12-27. Interventions recorded: Elacestrant, Alpelisib, Everolimus, Ribociclib, Palbociclib and Capivasertib.
Shares Menarini / Stemline, Elacestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Menarini / Stemline, Elacestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Menarini / Stemline, Elacestrant, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Ribociclib, Capivasertib, Palbociclib, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Ribociclib, Everolimus, Palbociclib, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Menarini / Stemline, Elacestrant, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Alpelisib, Palbociclib, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ribociclib, Palbociclib, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.